Biotech Values

[jfmcrr]

MRK’s presenter at the FDA adcomm just said that he has no valid explanation for the observed fall-off in Molnupiravir’s efficacy relative to placebo in the portion of the trial following the interim analysis other than that the placebo arm overperformed (LOL).

Prolly improper dosing or insufficient dilution of placebo. Subjects were subjected to excessively high levels of non treatment.